Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Fineline Cube Apr 30, 2026
Company Drug

HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia

Fineline Cube Apr 30, 2026
Company Medical Device

Acotec Scientific’s Peridge Catheter Receives NMPA Nod for Hemodialysis Lesion Treatment

Fineline Cube Feb 1, 2024

Acotec Scientific Holdings Ltd (HKG: 6669), a China-based medical device company, has announced that it...

Company Drug

Beijing Tiantan Biological Halts Phase III Clinical Trial for CMV Immunoglobulin Citing Strategic Reasons

Fineline Cube Feb 1, 2024

Beijing Tiantan Biological Products Co., Ltd (SHA: 600161), a biopharmaceutical firm based in China, has...

Company

WuXi XDC Forecasts Over 100% Revenue Growth for 2023 on Strength of ADC Industry

Fineline Cube Feb 1, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKEX: 2269) and WuXi STA,...

Company

GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion

Fineline Cube Feb 1, 2024

GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth...

Company

Novartis Sees Robust Growth in Innovative Medicines with 2023 Financials Reflecting a Shift Toward R&D Focus

Fineline Cube Feb 1, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, reported a substantial leap in its global sales...

Company Drug

Gilead’s Kite Subsidiary Reduces CAR T-Cell Therapy Turnaround Time with FDA Approval

Fineline Cube Feb 1, 2024

Kite, a subsidiary of Gilead (NASDAQ: GILD), has announced a significant enhancement in the treatment...

Company Deals

Junde Pharmaceuticals Licenses Weight-Reducing Capsule JTX-102 to Changchun GeneScience

Fineline Cube Feb 1, 2024

Xiamen Junde Pharmaceutical Technology Co., Ltd., a China-based pharmaceutical company, has entered into a licensing...

Company Deals

Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens

Fineline Cube Feb 1, 2024

Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing...

Company Deals

Kangtai Biological Products Co., Ltd. Expands Vaccine Access in South Asia with Bangladesh Deal

Fineline Cube Feb 1, 2024

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a Chinese biopharmaceutical firm, has announced the...

Company Deals

Smartnuclide Biopharmaceutical Partners with Gosun Pharmaceuticals for rhTSH Market Promotion in China

Fineline Cube Feb 1, 2024

Suzhou Smartnuclide Biopharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has entered into a business cooperation...

Company Deals

MindRank Ltd Partners with Henlius Biotech to Pioneer AI-Powered Drug Therapies

Fineline Cube Feb 1, 2024

MindRank Ltd, a China-based frontier in AI-enabled drug development, has inked a strategic partnership with...

Company Drug

Sandoz Launches Biosimilar Natalizumab in Germany, Challenging Biogen’s Tysabri

Fineline Cube Feb 1, 2024

Sandoz, a division of Novartis and a leader in generic drugs and biosimilars headquartered in...

Company Deals R&D

Siemens Healthineers AG and Shandong First Medical University’s College of Radiology Collaborate on Medical Imaging Metaverse

Fineline Cube Jan 31, 2024

Siemens Healthineers AG (ETR: SHL), a leading life sciences company based in Germany, has entered...

Company

Clinigen Expands Global Footprint with First Fully-Owned Subsidiary in Shanghai’s Free Trade Zone

Fineline Cube Jan 31, 2024

Clinigen, a UK-based medical and pharmaceutical services provider, has announced the establishment of its first...

Company Drug

European Commission Approves Takeda’s Hyqvia for Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Jan 31, 2024

The European Commission (EC) has granted regulatory approval to Takeda Pharmaceutical Company Limited (TYO: 4502)...

Company Deals

WuXi XDC Partners with Multitude Therapeutics and Signs MOU with Shanghai Huilian to Advance ADC Technologies

Fineline Cube Jan 31, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company

Shanghai Administration Imposes Hefty Fine on H&S Pharmaceutical for Substandard Drugs

Fineline Cube Jan 31, 2024

The Shanghai Municipal Medical Products Administration has disclosed that Hengshan (H&S) Pharmaceutical is under scrutiny...

Company

Shanghai Junshi Biosciences Forecasts 6.02% Revenue Growth in 2023 Driven by Commercialized Products

Fineline Cube Jan 31, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China,...

Company Deals

Regeneron Pharmaceuticals Acquires 2seventy Bio to Boost Cell Therapy Capabilities

Fineline Cube Jan 31, 2024

Regeneron Pharmaceuticals (NASDAQ: REGN) has announced the acquisition of U.S. biotechnology company 2seventy Bio Inc....

Policy / Regulatory

Hunan Province Hospitals Commit to Implementing Nationally Negotiated Drugs in Policy Seminar

Fineline Cube Jan 31, 2024

A policy seminar under the auspices of the Hunan Healthcare Security Administration bureau convened in...

Posts pagination

1 … 399 400 401 … 659

Recent updates

  • Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026
  • Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China
  • Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit
  • HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia
  • Novartis Q1 2026 Results Show Strong Brand Momentum Offset by Generic Erosion; FY Guidance Reaffirmed
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Company Medical Device

Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit

Company Drug

HutchMed’s Sovleplenib Granted NMPA Priority Review for Warm Antibody Autoimmune Hemolytic Anemia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.